To our best knowledge, this is the first study to demonstrate that plasma ICAM-1 significantly correlated with disease severity of corticosteroid resistant ITP patients, and initial ICAM-1 level might predict response to low-dose decitabine treatment. Here, ICAM1 is linked to autoimmune thrombocytopenic purpura.